The Alzheimer’s Association has published an analysis of a 2024 RAND report that outlines the health, community, and economic benefits of more systemic and deliberate investment in the treatment of Alzheimer’s disease in adults with Down syndrome.
The Alzheimer’s Association has published an analysis of a 2024 RAND report that outlines the health, community, and economic benefits of more systemic and deliberate investment in the treatment of Alzheimer’s disease in adults with Down syndrome.
The Alzheimer’s Association has published an analysis of a 2024 RAND report that outlines the health, community, and economic benefits of more systemic and deliberate investment in the treatment of Alzheimer’s disease in adults with Down syndrome.
PCORI funds study of new approach to Sleep Apnea treatment LuMind IDSC will serve as a key partner to researchers
Summer internship leads to new analysis of Down syndrome research activities This summer, LuMind IDSC welcomed two interns to support
In the beginning of 2025, following three nation-wide searches, LuMind IDSC welcomed new team members to the Administration, Community Engagement,
10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla.
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome
